• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune-related adverse events: what we've learned and where we're heading.

作者信息

Badran Yousef R, Leet Donna E, Dougan Michael

机构信息

Department of Medicine, Massachusetts General Hospital , Boston, MA, USA.

Medical Student, Harvard Medical School , Boston, MA, USA.

出版信息

Expert Rev Anticancer Ther. 2020 Sep;20(9):727-730. doi: 10.1080/14737140.2020.1803742. Epub 2020 Sep 1.

DOI:10.1080/14737140.2020.1803742
PMID:32726153
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8386140/
Abstract
摘要

相似文献

1
Immune-related adverse events: what we've learned and where we're heading.免疫相关不良事件：我们所了解的情况及未来发展方向。
Expert Rev Anticancer Ther. 2020 Sep;20(9):727-730. doi: 10.1080/14737140.2020.1803742. Epub 2020 Sep 1.
2
How can we manage the cardiac toxicity of immune checkpoint inhibitors?我们如何管理免疫检查点抑制剂的心脏毒性？
Expert Opin Drug Saf. 2021 Jun;20(6):685-694. doi: 10.1080/14740338.2021.1906860. Epub 2021 Apr 1.
3
Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis.免疫相关不良反应后免疫治疗再挑战的结果：系统评价和荟萃分析。
Immunotherapy. 2020 Nov;12(16):1183-1193. doi: 10.2217/imt-2020-0103. Epub 2020 Sep 3.
4
COVID-19 vaccination and cancer immunotherapy: should they stick together?COVID-19 疫苗接种和癌症免疫疗法：它们应该结合在一起吗？
Br J Cancer. 2022 Jan;126(1):1-3. doi: 10.1038/s41416-021-01618-0. Epub 2021 Nov 19.
5
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?免疫检查点抑制剂如何导致实体瘤的超进展？
Front Immunol. 2020 Mar 20;11:492. doi: 10.3389/fimmu.2020.00492. eCollection 2020.
6
Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy.接受免疫检查点抑制剂治疗患者的免疫治疗相关毒性管理
JAMA. 2021 Feb 2;325(5):482-483. doi: 10.1001/jama.2020.17308.
7
Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues.PD-1/PD-L1阻断免疫相关皮肤毒性的管理：观点与问题
Immunotherapy. 2021 Jul;13(10):795-798. doi: 10.2217/imt-2021-0071. Epub 2021 May 6.
8
Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.不同免疫检查点抑制剂方案相关免疫性结肠炎的差异风险。
Int Immunopharmacol. 2020 Oct;87:106770. doi: 10.1016/j.intimp.2020.106770. Epub 2020 Jul 21.
9
Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗相关不良事件的诊断、监测和管理。
Curr Oncol. 2020 Apr;27(Suppl 2):S43-S50. doi: 10.3747/co.27.5111. Epub 2020 Apr 1.
10
The effect of patient sex on the efficacy and safety of anticancer immunotherapy.患者性别对抗癌免疫治疗的疗效和安全性的影响。
Expert Opin Drug Saf. 2021 Dec;20(12):1535-1544. doi: 10.1080/14740338.2021.1939672. Epub 2021 Sep 1.

引用本文的文献

1
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion.癌症免疫治疗的现状：利用免疫武器库克服免疫逃逸
Biology (Basel). 2024 Apr 28;13(5):307. doi: 10.3390/biology13050307.

本文引用的文献

1
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.纳武利尤单抗治疗转移性非小细胞肺癌免疫相关不良事件的相关结局：一项全球队列的汇总探索性分析。
Cancer Immunol Immunother. 2020 Jul;69(7):1177-1187. doi: 10.1007/s00262-020-02536-5. Epub 2020 Mar 5.
2
Time to dissect the autoimmune etiology of cancer antibody immunotherapy.解析癌症抗体免疫疗法的自身免疫病因学。
J Clin Invest. 2020 Jan 2;130(1):51-61. doi: 10.1172/JCI131194.
3
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events.免疫检查点抑制剂与 TNFα 阻断剂联合治疗胃肠道免疫相关不良事件患者。
J Immunother Cancer. 2019 Aug 22;7(1):226. doi: 10.1186/s40425-019-0711-0.
4
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.分析接受程序性死亡蛋白 1 或程序性死亡配体 1 抗体治疗的患者不良事件与结局之间的关联。
J Clin Oncol. 2019 Oct 20;37(30):2730-2737. doi: 10.1200/JCO.19.00318. Epub 2019 May 22.
5
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.癌症免疫治疗后的不良反应：挑战与机遇。
Trends Immunol. 2019 Jun;40(6):511-523. doi: 10.1016/j.it.2019.04.002. Epub 2019 Apr 30.
6
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.预防性 TNF 阻断可使 CTLA-4 和 PD-1 免疫治疗的疗效和毒性脱耦联。
Nature. 2019 May;569(7756):428-432. doi: 10.1038/s41586-019-1162-y. Epub 2019 May 1.
7
Cancer immunoediting and resistance to T cell-based immunotherapy.癌症免疫编辑与 T 细胞免疫疗法抵抗。
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. doi: 10.1038/s41571-018-0142-8.
8
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.粪便微生物群移植治疗难治性免疫检查点抑制剂相关性结肠炎。
Nat Med. 2018 Dec;24(12):1804-1808. doi: 10.1038/s41591-018-0238-9. Epub 2018 Nov 12.
9
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.基线类固醇对非小细胞肺癌患者程序性细胞死亡-1 和程序性死亡配体 1 阻断疗效的影响。
J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.
10
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.非小细胞肺癌患者发生免疫相关不良事件后再次使用免疫治疗的安全性和疗效。
Cancer Immunol Res. 2018 Sep;6(9):1093-1099. doi: 10.1158/2326-6066.CIR-17-0755. Epub 2018 Jul 10.